These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33125822)

  • 1. The intra-individual stability of GH biomarkers IGF-I and P-III-NP in relation to GHRH administration, menstrual cycle, and hematological parameters.
    Ericsson M; Bhuiyan H; Yousif B; Lehtihet M; Ekström L
    Drug Test Anal; 2020 Nov; 12(11-12):1620-1628. PubMed ID: 33125822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers.
    Lehtihet M; Bhuiyan H; Dalby A; Ericsson M; Ekström L
    Drug Test Anal; 2019 Mar; 11(3):411-421. PubMed ID: 30223291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
    Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
    Kniess A; Ziegler E; Thieme D; Müller RK
    J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal studies of putative growth hormone (GH) biomarkers and hematological and steroidal parameters in relation to 2 weeks administration of human recombinant GH.
    Sieckmann T; Elmongy H; Ericsson M; Bhuiyan H; Lehtihet M; Ekström L
    Drug Test Anal; 2020 Jun; 12(6):711-719. PubMed ID: 32115881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.
    Equey T; Pastor A; de la Torre Fornell R; Thomas A; Giraud S; Thevis M; Kuuranne T; Baume N; Barroso O; Aikin R
    J Clin Endocrinol Metab; 2022 Feb; 107(3):649-659. PubMed ID: 34726230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
    Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
    Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
    Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluctuations in hematological athlete biological passport biomarkers in relation to the menstrual cycle.
    Mullen J; Baekken L; Bergström H; Björkhem Bergman L; Ericsson M; Ekström L
    Drug Test Anal; 2020 Sep; 12(9):1229-1240. PubMed ID: 32497419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle.
    Juul A; Scheike T; Pedersen AT; Main KM; Andersson AM; Pedersen LM; Skakkebaek NE
    Hum Reprod; 1997 Oct; 12(10):2123-8. PubMed ID: 9402266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
    Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
    J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker detection of rhGH doping: an excretion study.
    Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M
    Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration.
    Cowan DA; Moncrieffe DA
    Drug Test Anal; 2022 May; 14(5):808-819. PubMed ID: 34418311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
    Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T;
    J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
    Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
    Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.